. Few years later, final results of the ESTHER study and the E3N French cohort study confirmed the potential safety of transdermal estrogens with respect to thrombotic risk [6, 7] . Recently, a large cohort study set-up in a United-Kingdom health insurance database provided further evidence for a better thrombotic profile of transdermal estrogens as compared to oral estrogens [8] .
In this issue of Menopause, results of a cohort study comparing the risk of venous thromboembolism between oral and transdermal estrogens users in North America are presented [9] . This study was set-up from the Thomson Reuters MarketScan Among not hysterectomised women, progestogens are added to estrogens for preventing the risk of endometrial cancer associated to estrogens use [11] . Two
French studies have recently showed that the type of progestogens could also be closely implicated in the thrombotic risk [6, 7] . While micronised progesterone was not associated with an increase thrombotic risk, some of synthetic progestins could be thrombogenic. Therefore, important is to take into account both the route of estrogen administration and the type of progestogens for an overall evaluation of the HT thrombotic profile.
Stroke is another common adverse outcome of HT [2, 12] and reducing also the stroke risk now becomes a new challenge to further improve the benefit/risk profile of short-term HT. A large cohort study has recently found a differential association of oral and transdermal estrogens with the risk of stroke [13] . Contrary to oral estrogens, standard doses transdermal estrogens were not associated with an increased risk of stroke among postmenopausal women, suggesting another important advantage of transdermal estrogens as compared to oral estrogens. This result is all the more important since it could be biologically plausible. Indeed, it has been recently shown that increased thrombin generation, which may be detected in plasma of women using oral but not transdermal estrogens [14] , could have an important role in the etiology of stroke among postmenopausal women [15] . Thus, a hypercoagulabilty could at least in part explain the increased risk of stroke among women using oral estrogens and transdermal estrogens could be a safer option with respect this adverse outcome.
Uncertainty still remains regarding the role of HT on CHD among postmenopausal women. The re-analysis of WHI clinical trials by age or time since menopause has shown that hormone timing may play a crucial role in determining the coronary risk among HT users (the "timing hypothesis"). Women who initiated HT closer to menopause tended to have a reduced CHD risk than do women more distant from menopause [16] . Admittedly, a potential beneficial effect of transdermal estrogens on CHD close to menopause has never been investigated so far but is this potential positive effect an expected benefit of HT for recently postmenopausal women?
Currently, correction of menopausal symptoms is the only indication for estrogen use whatever the route of administration and other specific strategies can be used for preventing chronic diseases.
The findings by Laliberte et al together with previous studies may be of great clinical relevance in minimizing the risk of venous thromboembolism among women who require HT. For example, among 10,000,000 postmenopausal women including 20%
HT users, around 1,000 cases of pulmonary embolism could be avoided for one year by transdermal estrogens use and this safer option would be especially noticeable for women at high risk for venous thromboembolism risk. Nevertheless, in spite increasing evidence for a neutral effect of transdermal estrogens on the risk of venous thromboembolism, important is to notice that randomized controlled trials are needed to definitely demonstrate the safety of transdermal estrogens with respect to thrombotic risk. However, feasibility of such trials remains uncertain. .
